James Smith

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2814711/publications.pdf

Version: 2024-02-01

33 papers	2,650 citations	430874 18 h-index	414414 32 g-index
34 all docs	34 docs citations	34 times ranked	3022 citing authors

#	Article	IF	Citations
1	Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Natural Product Reports, 2013, 30, 108-160.	10.3	1,692
2	Occidiofungin, a Unique Antifungal Glycopeptide Produced by a Strain of Burkholderia contaminans. Biochemistry, 2009, 48, 8312-8321.	2.5	96
3	Elucidation of the Antimicrobial Mechanism of Mutacin 1140. Biochemistry, 2008, 47, 3308-3314.	2.5	71
4	Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Current Opinion in Microbiology, 2008, 11, 401-408.	5.1	70
5	Two Flavoenzymes Catalyze the Post-Translational Generation of 5-Chlorotryptophan and 2-Aminovinyl-Cysteine during NAI-107 Biosynthesis. ACS Chemical Biology, 2017, 12, 548-557.	3.4	64
6	Oxidation of Lanthionines Renders the Lantibiotic Nisin Inactive. Applied and Environmental Microbiology, 2009, 75, 1381-1387.	3.1	55
7	Genetic and Biochemical Map for the Biosynthesis of Occidiofungin, an Antifungal Produced by Burkholderia contaminans Strain MS14. Applied and Environmental Microbiology, 2011, 77, 6189-6198.	3.1	49
8	Structure and Dynamics of the Lantibiotic Mutacin 1140. Biochemistry, 2003, 42, 10372-10384.	2.5	48
9	Site-Directed Mutations in the Lanthipeptide Mutacin 1140. Applied and Environmental Microbiology, 2013, 79, 4015-4023.	3.1	47
10	Comparative genomeâ€wide analysis reveals that Burkholderia contaminans <scp>MS</scp>14 possesses multiple antimicrobial biosynthesis genes but not major genetic loci required for pathogenesis. MicrobiologyOpen, 2016, 5, 353-369.	3.0	44
11	Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics. FEBS Journal, 2000, 267, 6810-6816.	0.2	39
12	Evolution of Lantibiotic Salivaricins: New Weapons to Fight Infectious Diseases. Trends in Microbiology, 2020, 28, 578-593.	7.7	36
13	The Antifungal Occidiofungin Triggers an Apoptotic Mechanism of Cell Death in Yeast. Journal of Natural Products, 2013, 76, 829-838.	3.0	34
14	Occidiofungin's Chemical Stability andIn VitroPotency against Candida Species. Antimicrobial Agents and Chemotherapy, 2012, 56, 765-769.	3.2	33
15	A Novel Actin Binding Drug withIn VivoEfficacy. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	27
16	The Siderophore Product Ornibactin Is Required for the Bactericidal Activity of Burkholderia contaminans MS14. Applied and Environmental Microbiology, 2017, 83, .	3.1	25
17	Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2. Applied and Environmental Microbiology, 2018, 84, .	3.1	21
18	The Burkholderia contaminans MS14 ocfC Gene Encodes a Xylosyltransferase for Production of the Antifungal Occidiofungin. Applied and Environmental Microbiology, 2013, 79, 2899-2905.	3.1	20

#	Article	IF	Citations
19	Biosynthesis and Transport of the Lantibiotic Mutacin 1140 Produced by Streptococcus mutans. Journal of Bacteriology, 2015, 197, 1173-1184.	2.2	20
20	Nonclinical Toxicological Evaluation of Occidiofungin, a Unique Glycolipopeptide Antifungal. International Journal of Toxicology, 2012, 31, 326-336.	1.2	18
21	Multipronged approach for engineering novel peptide analogues of existing lantibiotics. Expert Opinion on Drug Discovery, 2015, 10, 857-870.	5.0	18
22	Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	17
23	Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and Stability. Applied and Environmental Microbiology, 2018, 84, .	3.1	17
24	Novel Antiparasitic Activity of the Antifungal Lead Occidiofungin. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	14
25	The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics. MicrobiologyOpen, 2014, 3, 961-972.	3.0	13
26	Toxicological Evaluation of Occidiofungin against Mice and Human Cancer Cell Lines. Pharmacology & Pharmacy, 2014, 05, 1085-1093.	0.7	13
27	The Presence of Two Cyclase Thioesterases Expands the Conformational Freedom of the Cyclic Peptide Occidiofungin. Journal of Natural Products, 2013, 76, 150-156.	3.0	11
28	Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery. Applied and Environmental Microbiology, 2017, 83, .	3.1	10
29	Drug discovery through the isolation of natural products from Burkholderia. Expert Opinion on Drug Discovery, 2021, 16, 807-822.	5.0	9
30	Optimization of the production of the lantibiotic mutacin 1140 in minimal media. Process Biochemistry, 2010, 45, 1187-1191.	3.7	8
31	Formulation, Pharmacological Evaluation, and Efficacy Studies of Occidiofungin, a Novel Antifungal. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	6
32	Improving the attrition rate of Lanthipeptide discovery for commercial applications. Expert Opinion on Drug Discovery, 2018, 13, 155-167.	5.0	4
33	Draft Genome Sequence of the Lantibiotic-Producing Strain Streptococcus salivarius HS0302. Microbiology Resource Announcements, 2019, 8, .	0.6	0